$30 M

UCBB Mkt cap, 31-Oct-2017
US-China Biomedical Technology Net income (FY, 2019)-710.9 K
US-China Biomedical Technology EBIT (FY, 2019)-522.1 K
US-China Biomedical Technology Cash, 28-Feb-201936.5 K

US-China Biomedical Technology Income Statement

Annual

USDFY, 2014FY, 2015FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

302.3k56.2k44.0k515.5k522.1k

Operating expense total

302.3k56.2k44.0k515.5k522.1k

EBIT

(844.9k)(218.9k)(522.1k)

Interest expense

10.7k3.9k

Pre tax profit

(1.0m)(56.2k)(44.0k)(481.3k)(710.1k)

Income tax expense

818.0800.0800.0906.0800.0

Net Income

(1.0m)(57.0k)(44.8k)(482.2k)(710.9k)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

R&D expense

General and administrative expense

40.7k75.5k57.0k20.6k23.2k12.5k18.9k20.7k12.8k40.0k229.9k129.0k274.6k143.0k

Operating expense total

40.7k75.5k57.0k20.6k23.2k12.5k18.9k20.7k12.8k40.0k229.9k398.9k274.6k143.0k

EBIT

(143.0k)

Interest expense

5.0k2.6k

Pre tax profit

(40.7k)(75.5k)(57.0k)(20.6k)(23.2k)(12.5k)(18.9k)(20.7k)(12.8k)(40.0k)(234.9k)(131.6k)(274.6k)(143.0k)

Income tax expense

(1.3k)

Net Income

(40.7k)(75.5k)(174.5k)(20.6k)(23.2k)(12.5k)(18.9k)(39.6k)(52.5k)(40.0k)(234.9k)(131.6k)(274.6k)(143.0k)

US-China Biomedical Technology Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2017FY, 2018FY, 2019

Cash

22.02.7k3.4k56.4k36.5k

Accounts Receivable

3.6m

Current Assets

61.4k58.3k

Total Assets

197.02.9k6.0k80.6k77.5k

Accounts Payable

78.9k29.4k14.2k18.2k21.6k

Total Liabilities

150.6k14.2k352.4k76.1k

Additional Paid-in Capital

1.2m1.7m1.7m1.9m2.9m

Retained Earnings

(1.7m)(1.7m)(2.2m)(2.9m)

Total Equity

(150.4k)(27.8k)(8.1k)(271.8k)1.4k

Financial Leverage

0 x-0.1 x-0.7 x-0.3 x55 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

232.068.0621.0188.0632.06.3k16.0k4.3k1.4k1.4k2.1k6.0459.5k340.2k

Current Assets

477.2k353.0k

Total Assets

407.0243.0796.036.9k807.06.5k26.2k12.0k6.5k11.6k9.7k5.0k496.4k372.3k

Accounts Payable

36.3k46.7k85.6k56.6k43.9k48.3k32.9k29.4k30.8k46.6k61.3k110.7k23.5k40.1k

Total Liabilities

142.7k183.5k58.3k45.5k50.0k59.7k242.8k344.6k58.7k77.5k

Additional Paid-in Capital

1.2m1.3m1.3m1.6m1.6m1.6m1.7m1.7m1.7m1.7m1.8m1.8m2.9m2.9m

Retained Earnings

(1.7m)(1.7m)(1.7m)(1.7m)(1.7m)(1.8m)(1.8m)(2.0m)(2.2m)(2.5m)(2.6m)

Total Equity

(142.3k)(183.3k)(178.6k)(21.4k)(44.7k)(43.5k)(6.7k)(17.4k)(24.3k)(48.1k)(233.0k)(339.6k)437.7k294.7k

Financial Leverage

0 x0 x0 x-1.7 x0 x-0.1 x-3.9 x-0.7 x-0.3 x-0.2 x0 x0 x1.1 x1.3 x

US-China Biomedical Technology Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2017FY, 2018FY, 2019

Net Income

(1.0m)(57.0k)(44.8k)(482.2k)(710.9k)

Accounts Payable

52.6k(49.5k)(16.5k)4.0k(5.7k)

Cash From Operating Activities

(285.9k)(114.4k)(63.8k)(400.9k)(544.7k)

Cash From Investing Activities

125.0

Cash From Financing Activities

198.5k117.0k64.5k453.9k524.8k

Interest Paid

10.0k

Income Taxes Paid

818.0800.0906.0800.0

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(40.7k)(116.1k)(174.5k)(20.6k)(43.8k)(56.2k)(18.9k)(39.6k)(52.5k)(40.0k)(274.9k)(406.5k)(274.6k)(417.6k)

Accounts Payable

6.1k16.5k55.4k27.2k14.3k18.8k2.2k(1.3k)143.032.5k47.2k96.6k5.3k21.9k

Cash From Operating Activities

(11.8k)(12.2k)(12.3k)(50.3k)(86.4k)(94.4k)(26.7k)(48.4k)(57.3k)(2.0k)(166.3k)(223.0k)(121.7k)(241.0k)

Long-term Borrowings

(45.0k)

Cash From Financing Activities

12.0k12.2k12.9k50.5k87.0k100.7k40.0k50.0k56.0k165.0k219.7k524.8k524.8k

Interest Paid

Income Taxes Paid

800.0800.0

US-China Biomedical Technology Ratios

USDY, 2019

Financial Leverage

55 x